INTRODUCTION

World Health Organization estimated that approximately 170 million individuals of the world population are diagnosed to be infected with Hepatitis C Virus (HCV).1 It is the most common blood-borne infection in USA.2 The prevalence rate of anti-HCV antibodies in Pakistan reported mostly by hospital based studies in patients, blood donors and in general population is 0.5-25.7%.3-9 Around 20% of persons with HCV infection experience progressive liver disease leading to cirrhosis or hepatocellular carcinoma over 20-40 years.10 No vaccine is currently available to prevent this chronic disease. The goals of therapy are to slow the pace of disease progression, reduce the infectivity and decrease the risk of hepatocellular carcinoma.

Combination therapy with INF-alpha-2b and ribavirin has resulted in two to three folds improvement in virological response to the disease. The effects of combination therapy are thought to be two folds, antiviral mechanisms and immunomodulation.11 INF-alpha-2b and ribavirin may trigger production of different types of non-specific and specific auto-antibodies such as antinuclear antibodies, rheumatic factor and anti-thyroid antibodies.12 In most cases, these antibodies do not produce clinically significant diseases. Minor adverse effects have been reported with combination therapy. Thyroid dysfunction, which has been reported to occur from 3.9 – 33.33%, is the most common autoimmune disorder associated with combination therapy.13-16 Therefore, it is necessary that thyroid functions are monitored during INF therapy and the course of thyroid disease is watched once autoimmune thyroid disorder develops during INF-alpha treatment.

The objective of the study was to evaluate frequency and type of thyroid dysfunction among patients of chronic hepatitis C during treatment with combined INF-alpha-2b and ribavirin therapy at Military Hospital, Rawalpindi.
Thyroid dysfunction following interferon and ribavirin therapy in chronic hepatitis C patients

Patients who were awaiting treatment subsequently for 24 weeks and control group comprising of 60 patients with immediate planned treatment. Patients were divided into two groups, treatment group comprising of 107 patients with IFN and/or ribavirin, history of pre-existing thyroid disease, neoplastic, autoimmune, severe cardiac or pulmonary disease, those currently using immunosuppressant and/or steroids and pregnant patients. Patients were treated with Interferon alpha 2b (INF) three million units subcutaneously three times a week and ribavirin 800-1200 mg orally daily for 24 weeks. Biochemical variables as described above were determined in treatment groups before the start of therapy, at 12 weeks during therapy and at 24 weeks at the end of INF therapy. In treatment group, response to therapy was determined by HCV RNA by PCR test at the end of 24 weeks therapy. In control group, S. ALT, S. TSH, S. Free T4 and S. total T3 were performed at weeks 0, 12 and 24.

Statistical analysis was done on SPSS 15. Mean and standard deviation of age, S. ALT, S. TSH, S. Free T4 and S. total T3 were determined. Frequency of thyroid dysfunction was also determined. Relative Risk (RR) ratio and Attributable Ratio (AR %) were calculated. Independent student's t-test was applied to S. ALT and S. AST levels. Statistical significance was set at < 0.05.

ETHICAL CONSIDERATION: Control group patients were those patients awaiting commencement of therapy. Their treatment was neither denied nor delayed. These patients had positive anti-HCV antibodies and persistently raised S. ALT levels. They were screened for HCV RNA by PCR for final diagnosis. Diagnosed cases were selected by non-probability convenience sampling as control group patients at this stage. Diagnosed cases were then admitted in the hospital for liver biopsy to determine the severity of disease. At the time of sampling in 2006 in this study setting, liver biopsy was mandatory before the commencement of treatment. After histopathology report, their cases were sent to concerned authorities for approval of funds. Control group patients were military personnel from all over the country, entitled for medical treatment, free of cost as indoor patients in tertiary care hospitals. Once funds were approved, these patients were admitted for commencement of INF therapy as indoor cases. It takes about 06-07 months for the whole process of initial admission, liver biopsy procedure, histopathology report, sanction of funds and final admission for commencement of treatment. During this time, patients were included in the study by non-probability convenience sampling technique as control group, keeping in view inclusion and exclusion criteria.

Study group patients were selected by non-probability convenience sampling technique from those patients who had already undergone liver biopsy; their funds had been sanctioned and were admitted in hospital for commencement of the INF therapy.

RESULTS

The demographic and baseline values of liver function tests and thyroid function tests are shown in Table I. In the treatment group, among 107 patients of chronic hepatitis C (80 males and 27 females), having ages between 18-48 years, 24 weeks after INF-alpha-2b and ribavirin therapy, 20 patients; 10 females and 10 males (18.69%) developed thyroid dysfunction. In the control group, one of the patients developed sub-clinical hyperthyroidism at 24 weeks.

The frequency of hypothyroidism was 8.4% (45% of positive cases) while that of hyperthyroidism was 7.5% (40% of positive cases), 2.8% of patients (15% of positive cases) exhibited biphasic thyroiditis i.e. transient hyperthyroidism at 12 weeks followed by hypothyroidism at 24 weeks of therapy. Thyroiditis was determined by thyroid scan in which thyroid gland showed increased radioisotope dye uptake initially, which was manifested as hyperthyroidism followed by decreased uptake of radioisotope dye, which was manifested as hypothyroidism.

Thyroiditis was detected within 12 weeks of initiation of INF therapy in 08 patients (40% of positive cases) while in 12 patients (60% of positive cases) at the end of 24 weeks treatment. Relative risk (RR) ratio was calculated to be 11.25 and attributable risk (AR%) was 91. Among positive cases, the incidence of symptomatic thyroid disease was found to be 7.47% (40% of positive cases) and sub-clinical cases were 11.21% (60% of positive cases). Symptomatic patients were 8 in number (40% of positive cases) out of which 3 (15% of positive cases) were hyperthyroid. They had sign and symptoms of hyperthyroidism comprising of palpitation, weight loss, anorexia, rapid pulse and tremors. All 3 patients were given anti-thyroid drug; neomercazole. All the patients completed INF therapy. Five patients (25% of positive cases) among symptomatic patients were clinically hypothyroid. They
had sign and symptoms of hypothyroidism comprising of constipation, lethargy, weight gain and sleep disturbances. There were 37.03% of females as compared to 12.5% of male patients who developed thyroid dysfunction (p=0.001). Eighty four percent of chronic hepatitis C patients showed favourable response depicted by HCV RNA by PCR to combined interferon and ribavirin therapy. Eighty eight percent of them at 12 weeks and 97% of them at the end of 24 weeks treatment showed normalization of S. alaninetrans-ferase levels (Table III). There was no significant association between severity of the disease and development of thyroid dysfunction (p=0.81). No significant association was found between response to therapy and occurrence of thyroid disease (p=0.79). All the patients completed antiviral therapy. None of the patients had to discontinue therapy because of thyroid dysfunction or any other side effects.

Table I: Demographic features and baseline values of liver function tests and thyroid function tests (n=167).

<table>
<thead>
<tr>
<th>Features</th>
<th>Study group (n=107)</th>
<th>Control group (n=60)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>Mean (SD)</td>
<td>Mean (SD)</td>
</tr>
<tr>
<td>Sex M/F</td>
<td>36 (6.7)</td>
<td>41.39 (9.6)</td>
</tr>
<tr>
<td>S. ALT (IU/L)</td>
<td>92.82 (62.83)</td>
<td>69.77 (41.36)</td>
</tr>
<tr>
<td>S. AST (IU/L)</td>
<td>59.65 (42.47)</td>
<td>55.46 (34.7)</td>
</tr>
<tr>
<td>S. T3 (nmol/l)</td>
<td>1.80 (0.22)</td>
<td>1.84 (0.21)</td>
</tr>
<tr>
<td>S. T4 (pmol/l)</td>
<td>14.42 (2.69)</td>
<td>14.37 (1.91)</td>
</tr>
<tr>
<td>S. TSH (mU/L)</td>
<td>1.09 (0.63)</td>
<td>1.03 (0.59)</td>
</tr>
</tbody>
</table>

Table II: Frequencies of thyroid dysfunction among chronic hepatitis C patients after 12 and 24 weeks of interferon and ribavirin therapy (n=107).

<table>
<thead>
<tr>
<th>Thyroid status</th>
<th>At 12 weeks</th>
<th>At 24 weeks</th>
</tr>
</thead>
<tbody>
<tr>
<td>Euthyroid</td>
<td>99 (92.5%)</td>
<td>87 (81.3%)</td>
</tr>
<tr>
<td>Hyperthyroid</td>
<td>4 (3.7%)</td>
<td>8 (7.5%)</td>
</tr>
<tr>
<td>Hypothyroid</td>
<td>3 (2.8%)</td>
<td>9 (8.4%)</td>
</tr>
<tr>
<td>Biphasic thyroiditis*</td>
<td>1 (0.9%)</td>
<td>3 (2.8%)</td>
</tr>
</tbody>
</table>

*Biphasic thyroiditis means transient hyperthyroidism after 12 weeks of therapy followed by hypothyroidism after 24 weeks of therapy.

Table III: S. alaninetransferase levels in treatment group and controls at weeks 12 and 24 of therapy (n=167).

<table>
<thead>
<tr>
<th>S. alaninetransferase (ALT) (UI/L)</th>
<th>Treatment group (n=107)</th>
<th>Controls (n=60)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean (SD)</td>
<td>Mean (SD)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline</td>
<td>92.82 (62.83)</td>
<td>69.77 (41.36)</td>
<td>&lt; 0.06</td>
</tr>
<tr>
<td>At 12 weeks</td>
<td>38.6 (30.74)</td>
<td>63.68 (30.08)</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>At 24 weeks</td>
<td>33.85 (24.02)</td>
<td>68.18 (54.6)</td>
<td>&lt; 0.001</td>
</tr>
</tbody>
</table>

DISCUSSION

INF alpha-2b and ribavirin therapy has known association with development of autoimmune thyroid disease in patients of chronic hepatitis C during treatment. Substantial research work has been carried out to determine the relationship of thyroid dysfunction and INF therapy. In this study, the incidence of thyroid dysfunction during INF and ribavirin therapy was 18.69% among 107 patients of chronic hepatitis C, undergoing 24 weeks treatment. Previous studies have reported an incidence between 3.9–33.33%. Present finding was consistent with most of the studies. Moreover, 8.4 % of patients (45% of positive cases) had hypothyroidism, 7.47% of patients (40% of positive cases) had hyperthyroidism while 2.8% (15% of positive cases) had biphasic thyroiditis. Hypothyroidism was found to be more common in the study as is the case in most of the studies. The incidence of symptomatic thyroid disease in this study was found to be 7.47% (40% of positive cases) and sub-clinical cases were 11.21% (60% of positive cases) in accordance with other studies. Bini et al. revealed the ratio of overt and sub-clinical thyroid disease being 6.7% and 4% (62% and 38%). In this study, 02 patients (10% of positive cases), who showed sub-clinical manifestations at 12 weeks of therapy, developed symptomatic disease at the end of treatment. Six patients (30% of positive cases) developed sub clinical picture at the end of therapy. The possibility of some of them later developing symptomatic overt disease cannot be ruled out and needs long-term follow-up of the patients.

In this study, 2.8% of total patients (15% of positive cases) showed biphasic thyroiditis in accordance with Moncouchy et al. who showed an incidence of 13.3% of positive cases. Treatment response in this study was 84% similar to that of other local studies.

A sustained virological response to INF and Ribavirin is associated with HCV specific and non-specific immunity. It was speculated that activated non-specific immunity may be associated with increased risk of autoimmunity, suggesting a correlation between the virological response to INF-alpha-2b and risk of developing thyroid dysfunction during treatment. Such an association has been reported in some studies in which development of hypothyroidism in patients with thyroid auto-antibodies undergoing treatment with IFN-alpha-2b plus ribavirin is significantly associated with the long-term remission of the disease. While other studies show that thyroid dysfunction during treatment of chronic hepatitis C with interferon-alpha has no association with either interferon dosage or efficacy of therapy. However, in this study, no significant relation
Thyroid dysfunction following interferon and ribavirin therapy in chronic hepatitis C patients

was found in virological treatment response to INF-alpha and ribavirin in patients with and without thyroid function. In fact, only 3 out of 20 patients (16%) revealing INF induced thyroid disease showed non-response to treatment while 14 patients without treatment out of 87 (13.79%) did not respond to treatment. The difference between the two was not statistically significant. One probable explanation can be that the immune mechanisms, which are involved in the pathogenesis of thyroid autoimmune phenomenon, are not the same which regulate the therapeutic response to HCV or modulate the unfavourable course of HCV-related chronic hepatitis C.30 The results are in accordance with the other studies, which revealed that neither severity of the disease nor the duration of therapy are related to occurrence of thyroid disease.14

In this study, effects on thyroid function were determined, induced by 24 weeks treatment with INF. Whether prolonged therapy, as given for 48 weeks in HCV genotype 1 and 4 patients, will increase the likelihood of INF induced thyroid disease cannot be answered although international studies reveal the negative correlation between the two.30 In most studies, the possibility of female gender being the independent predictors of INF induced thyroid disease has been determined.17,33,36

In this study, the statistical difference between the two genders developing thyroid disease was highly significant. In fact, 37.03% of females as opposed to 12.5% of males experienced thyroid dysfunction during treatment, confirming the previous data in literature, and difference was highly significant statistically. Whether thyroid disease, induced by INF and ribavirin, resolves spontaneously or needs long-term treatment in patients of this study can not be answered because long-term follow-up could not be done. Other studies showed that approximately 02% of patients, suffering from INF induced thyroid dysfunction, required long-term treatment for thyroid dysfunction.31-33

CONCLUSION
Compared INF-alpha-2b and ribavirin therapy induced thyroid dysfunction (both hyperthyroidism and hypothyroidism, later being more common) in patients of chronic hepatitis C. Females were at a higher risk to develop INF induced thyroid dysfunction.

REFERENCES


